Association between serum 25-hydroxyvitamin D and the effects of Angiotensin II receptor blocker on renal function among African Americans: A post hoc analysis of a randomized placebo-controlled trial.

What Was Tested

This randomized controlled trial looks at Angiotensin II.

Sixty-four participants were included in this ancillary study from a randomized, double-blind, placebo-controlled, crossover trial among normotensive African Americans to test the effect of ARB on stress response of blood pressure and renal sodium handling.

Why It Was Studied

The researchers tested the hypothesis that vitamin D status may modify the effect of Angiotensin II receptor blocker (ARB) on renal function among African Americans.

On the final day of each intervention, the participant underwent a mental stress test.

Who Took Part

PubMed indexes the participants as teenagers, young adults and adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and crossover.

Random assignment meant chance, not the researchers, decided who got Angiotensin II and who got the comparison, which limits bias.

Neither the participants nor the staff measuring them knew who was on Angiotensin II, so expectations could not easily colour the readings.

Some participants received a placebo instead of Angiotensin II, giving a reference point.

Each person switched between Angiotensin II and the comparison at some point, usually with a gap in between.

Baseline serum 25-hydroxyvitamin D [25(OH)D] level was measured in this ancillary study.

What Was Measured

The researchers tested the hypothesis that vitamin D status may modify the effect of Angiotensin II receptor blocker (ARB) on renal function among African Americans.

On the final day of each intervention, the participant underwent a mental stress test.

The subject headings attached to it are Black or African American, Angiotensin Receptor Antagonists, Hypertension and Vitamin D.

The authors tagged it with the keywords Angiotensin II and renal function.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Angiotensin II.

The publication is from 2020 (Journal of clinical hypertension (Greenwich, Conn.)), a journal based in United States.

More context: the Angiotensin II compound page, all human trials.